Biogen_Logo_Standard-rgb_R.jpg
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
March 06, 2024 07:30 ET | Biogen Inc.
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZAReductions in biomarker complement...
Biogen_Logo_Standard-rgb_R.jpg
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
March 04, 2024 16:15 ET | Biogen Inc.
New data advances understanding of new approaches to treating Alzheimer’s diseaseResearch on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 (GLOBE...
Biogen_Logo_Standard-rgb_R.jpg
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
February 23, 2024 07:00 ET | Biogen Inc.
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the development...
Biogen_Logo_Standard-rgb_R.jpg
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
February 12, 2024 16:06 ET | Biogen Inc.
Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorderTreatment with SKYCLARYS improved patient function compared to placeboBiogen is leveraging its...
Biogen_Logo_Standard-rgb_R.jpg
Biogen to Realign Resources for Alzheimer's Disease Franchise
January 31, 2024 07:30 ET | Biogen Inc.
Company to reprioritize resources allocated to ADUHELM® (aducanumab-avwa) to advance LEQEMBI® (lecanemab-irmb) and to develop new treatment modalitiesBiogen committed to building a leading Alzheimer’s...
Biogen_Logo_Standard-rgb_R.jpg
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
December 19, 2023 07:30 ET | Biogen Inc.
CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions...
Biogen_Logo_Standard-rgb_R.jpg
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
December 15, 2023 09:05 ET | Biogen Inc.
Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1Milestone highlights Biogen’s growing portfolio in rare diseases and focus on addressing unmet needs of...
Biogen_Logo_Standard-rgb_R.jpg
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
December 14, 2023 06:30 ET | Biogen Inc.
ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD Patient...
Biogen_Logo_Standard-rgb_R.jpg
Biogen Appoints Monish Patolawala to its Board of Directors
November 06, 2023 07:30 ET | Biogen Inc.
Biogen Appoints Monish Patolawala to its Board of Directors
Biogen_Logo_Standard-rgb_R.jpg
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer’s Disease (CTAD) Conference
October 25, 2023 17:26 ET | Biogen Inc.
Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patients Showed No Decline And 60% Showed Clinical...